>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • MAMA -5.3%
Other news:
  • PAC -5% (acquires 51.5% of the shares representing the capital stock of the Company "GWTC")
  • NVGS -2.8% (prices offering of 7 mln shares of common stock at $15.00 per share)
  • ACN -1.8% (CFO retires, names new CFO; makes other mgmt changes)
  • MTDR -1.3% (entered into a definitive agreement to acquire a subsidiary of Ameredev II Parent)
  • NRIX -0.9% (files mixed shelf securities offering)
Analyst comments:
  • BIRK -2.6% (downgraded to Neutral from Buy at Goldman)
  • PSTG -2.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • ASO -2.3% (downgraded to Neutral from Buy at UBS)
  • NEE -1.8% (downgraded to Neutral from Buy at Mizuho)
  • PARA -1.8% (downgraded to Underweight from Equal Weight at Wells Fargo)
  • BBVA -1.6% (downgraded to Underperform from Neutral at Exane BNP Paribas)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • ORCL +8% (also forms form multi-cloud partnership with Google Cloud; also OpenAI selects Oracle to extend Microsoft Azure AI platform), CASY +4.7% (also increases dividend), RBRK +3.1%, ESI +1.3%
Other news:
  • RTO +12.2% (Trian Fund amasses significant stake, according to Bloomberg)
  • MREO +6.5% (Ultragenyx and Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta)
  • DNTH +5.2% (FDA clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy)
  • IOVA +5.1% (disclosed stockholders' vote on five proposals)
  • RARE +4.2% (Ultragenyx and Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta)
  • PRLD +4.2% (provides investor updates and milestone timeline in presentation)
  • RNA +3.6% (Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy)
  • ARAY +3.4% (approval of the Accuray Precision treatment planning system by China's National Medical Products Administration)
  • MAMO +3.1% (MAMO and BTOC announce strategic partnership)
  • SCLX +3% (announces 5-year term of $100 million financing with royalty-based payments and potential strategic transactions with Perigrove and its portfolio companies)
  • SUZ +2.2% (acquires a 15% stake in Lenzing AG from B&C Group)
  • DNLI +2.1% (FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies)
  • SMFG +1.8% (responds to ISS Report)
  • AB +1.6% (reports May AUM)
  • VCTR +1.5% (reports May AUM)
  • SAVE +1.2% (negotiations with bondholders are progressing as expected; co also delays Analyst Day)
Analyst comments:
  • KVYO +3.9% (upgraded to Overweight from Equal Weight at Barclays)
  • NGG +3.5% (upgraded to Buy from Neutral at Goldman)
  • CIEN +2.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
  • HAE +2% (upgraded to Buy from Hold at Needham)
  • DAR +1.7% (upgraded to Buy from Neutral at Citigroup)
  • MKC +1.1% (upgraded to Neutral from Sell at Citigroup)

FT : What does Peltz want from Rentokil?

What does Peltz want from Rentokil?
Simply the pest

“Does Nelson Peltz understand termites?” is a question we’d not thought to ask before today. Per MainFT:

Shares in Rentokil surged more than 15 per cent on Wednesday after it emerged that activist investor Nelson Peltz’s Trian Partners had taken a stake in the world’s largest pest control company.

The shares were the biggest gainers on the FTSE 100, driving Rentokil’s market capitalisation to £11.9bn.

The London-listed group has struggled in recent months with a slowdown in demand in the US, which accounts for more than half its sales following its $6.7bn acquisition of Terminix in 2021.

Trian said that it has a “significant position” in Rentokil, making it a top-10 shareholder. It “has reached out to Rentokil to discuss ideas and initiatives to improve shareholder value,” the firm said, adding that it “looks forward to working with Rentokil’s leadership team”.

The most obvious thing to do with Rentokil is to relist it in the US, where there’s a big valuation gap with closest peer Rollins and smaller rivals like Citra and Ecolab. But the valuation gap partly reflects Rentokil’s recent loss of market share to those companies. It’s not just a UK market thing.

US pest control grew 3.1 per cent organically for Rentokil in 2023, versus 8 per cent growth for Rollins. For 2024, Rentokil has guided for organic growth of 2-4 per cent, which would be below its long-term estimate that the US market has been growing at 4.3 per cent a year.

America’s pest control sector is fragmented and locally segmented, and Rentokil is a decentralised organisation that was built by acquisition. It still has around 80 brands in the US, nearly all of which are not wanted, so there’s a lot of rebranding required before its strategy of promoting Terminix as the answer to any infestation can pay off.

Before Peltz showed up, Rentokil investors had written off 2024 as a transition year. Management warned with 2023 results that full integration of Terminix had been pushed back by a year to 2026, so its employees don’t get much in the way of job security.

In addition to the rebrandings, there’s a round of US branch closures, with 125 to be shuttered by 2025 as part of a strategy to create regional Terminix offices that generate $8-10mm in revenue per annum. It’s ambitious and atypical: Rollins prefers a tiered structure where local offices aim to do just $3mm a year.

Rentokil management spent last year arguing that slowing growth was on weaker consumer demand that was much less apparent in rivals’ results. Investors have preferred to see its problems as self-inflicted by ambition so, awaiting proof that the Terminix restructuring will work, the stock had been trading at about 10 times 2025 ebitda. It’s a huge discount to Rollins’ rating of about 27 times 2025 ebitda but given the scale of the job it’s hardly an irrational one.

So. What does Peltz want done better? Breaking up Rentokil might help focus some minds and clear some desks. About 20 per cent of group revenue comes from a hygiene division and a French workwear business that gets little attention from investors.

Another possibility would be that he will encourage a takeover bid, Cadbury style. Pest control is too fragmented a market globally for a merger to raise significant antitrust concerns and private equity firms have been rolling up smaller operators, including the UK arm of Terminix. But any buyer would be inheriting the same problems faced by long-serving Rentokil CEO Andy Ransom, so it’s hard to argue for a dramatically higher valuation.

Rentokil’s historic US market share of about 27 per cent means it has a #1 position in US pest control and its North America business accounts for about 63 per cent of revenue. There are good reasons why Rentokil might be a better fit in New York than in London, but the relocation maths is not as simple as transplanting the high valuations given to its peers. Peltz has a good record for spotting hidden value, but what he knows about killing termites is unproven.

FT : EU to impose multibillion-euro tariffs on Chinese electric cars

EU to impose multibillion-euro tariffs on Chinese electric cars
Brussels moves ahead with additional duties of up to 25% despite opposition from Germany

Brussels is pushing ahead with Chinese electric vehicle tariffs that are set to bring in more than €2bn a year, brushing aside German government warnings that the move risks starting a costly trade war with Beijing.

The European Commission is to notify carmakers on Wednesday that it will provisionally apply additional duties of up to 25 per cent on imported Chinese EVs from next month, according to people familiar with the decision.

Brussels argues that Chinese EV makers benefit from subsidies that undercut their European rivals.

The tariffs, championed by France and Spain, will raise billions of euros for the EU budget annually as sales of Chinese EVs grow in Europe. China, the bloc’s largest trading partner, exported €10bn of electric cars to the EU in 2023, doubling its market share last year to 8 per cent, according to analysts at Rhodium Group.

Beijing has warned it would retaliate as it seeks to persuade a majority of EU capitals to oppose the new tariffs, which would be on top of the bloc’s existing 10 per cent duties. Beijing is already applying a 15 per cent tariff on European EVs.

Germany, Sweden and Hungary have said they do not approve of the move, fearing Chinese retaliation. EU officials say Berlin put pressure on Ursula von der Leyen, who is seeking a second term as commission president, to drop the anti-subsidy investigation.

German Chancellor Olaf Scholz recently warned that “isolation and illegal customs barriers . . . ultimately just makes everything more expensive, and everyone poorer”.

But intense lobbying by Scholz’s government “has not worked”, said a person briefed on the process. The commission was expected to increase its duties to about 35 per cent, the person said, still well short of the 100 per cent duties applied by the US.


The additional tariffs in Europe will hit Chinese producers including BYD and SAIC, as well as companies such as Tesla which have factories in China. The duties may vary according to producer, depending on the level of subsidy the EU claims it has identified.

The Kiel Institute, an economic think-tank, found that an extra 20 per cent tariff on Chinese electric cars would reduce imports by a quarter. It calculated that with 500,000 vehicles imported in 2023, this corresponded to an estimated 125,000 units worth almost $4bn.

“The decline would largely be offset by an increase in production within the EU and a lower volume of EV exports, which would likely mean noticeably higher prices for end consumers,” the researchers concluded.  

The commission expects Chinese EVs to hold a 15 per cent market share in the EU next year. It says prices are typically 20 per cent lower than those of EU-made models.

Valdis Dombrovskis, EU trade commissioner, acknowledged EVs were crucial for the green transition when he announced the investigation in October. But he added: “Competition must be fair.”

His department had amassed evidence that Chinese carmakers and their suppliers received subsidised loans, tax breaks and cheap land, according to officials.

China’s foreign ministry spokesperson Lin Jian on Wednesday dismissed the EU’s anti-subsidy investigation as “a typical example of protectionism”, adding that the decision to impose additional tariffs “violates market economy principles and international trade rules”.

“Protectionism has no future,” he said. “Open co-operation is the right path.”

Many EU carmakers have condemned the plan, fearing China might respond in kind or even block them from its market. European brands accounted for about 6 per cent of EV sales in the country in 2022.

Germany exported 216,299 cars to China in 2023, a drop of 15 per cent on the year before; brands including Mercedes and Volkswagen also operate plants in the country.

Geely, one of the Chinese companies under investigation, owns Volvo of Sweden. Prime Minister Ulf Kristersson has joined Scholz and Hungarian premier Viktor Orbán, who has courted Chinese EV investment, in publicly opposing the EU tariffs.

The three leaders would need to secure at least 11 other governments to overturn the commission’s decision on tariffs. Other central European countries such as the Czech Republic and Slovakia are expected to join the opposition.

Exporters of food and luxury goods such as Italy are also concerned about retaliation against products from the country.

But France, which pushed for the investigation to protect its own industry and force China to invest in production there, is unlikely to bend. Spain, another big car producer, has also indicated it would back tariffs.

Member states will be asked to vote on the tariffs before November 2. Definitive duties are usually imposed for five years.

FT : Battery specialist Umicore warns on EV slowdown

Battery specialist Umicore warns on EV slowdown
Belgium group says demand from carmakers has deteriorated in recent weeks

One of the world’s largest makers of battery materials has warned of a rapid deterioration in demand as the once booming electric vehicle market slows.

Umicore, which makes materials used in cathodes, the most expensive part of an electric vehicle battery, on Wednesday pointed to the “sharp slowdown in the growth of demand for EVs”.

As a result, the Belgium-based company said: “2024 volumes for its battery materials could be equal or slightly lower than last year.”

The warning from Umicore, which competes with Germany’s BASF and a series of Chinese companies, is the latest evidence of how slowing EV sales growth is reverberating across the industry’s supply chain.

“Our short-term outlook in Battery Materials is clearly disappointing,” said chief executive Bart Sap, who was appointed in May. “We are adapting our pace to this new reality and are taking the necessary actions to navigate the immediate challenges.”

With demand weakening, Umicore said its battery materials business would only break even this year compared with an earlier forecast of a €135mn profit. The company counts Volkswagen and BMW as customers.

>>> Europe : Brokers Upgrades & Downgrades - 12th of June 2024 V2(+)

>>> Up
* Credit Agricole Raised to Buy at Jefferies; PT 21.60 euros
* Exel Composites Raised to Accumulate at Inderes
* Fnac Darty Raised to Neutral at Oddo BHF
* GB Group Raised to Buy at Canaccord; PT 455 pence (+)
* Howden Joinery PT Raised to 1,210 pence at Deutsche Bank (+)
* KGHM Raised to Neutral at JPMorgan; PT 140 zloty
* Oxford Instruments PT Raised to 3,000 pence at Deutsche Bank (+)
* Saipem Raised to Add at AlphaValue/Baader

>>> Down
* BBVA Cut to Underperform at BNPP Exane; PT 9.40 euros (+)
* Birkenstock Cut to Neutral at Goldman; PT $58
* Gofore Cut to Reduce at Inderes; PT 26 euros
* Greenvolt Cut to Neutral at Oddo BHF
* Paramount Global Cut to Underweight at Wells Fargo; PT $9

>>> Initiation
* AMD Rated New Buy at Edward Jones
* Arverne Group Rated New Outperform at Oddo BHF; PT 9 euros
* Heidelberg Materials Re-Initiated Buy at Bankhaus Metzler (+)
* St James's Place Reinstated Buy at Peel Hunt; PT 750 pence

>>> Call
* Credit Agricole Raised at Jefferies on Pullback in French Banks

>>> Stoxx 600 Pre-Market Indications

  • Rentokil (RTO1 TH) +7.6%
    • Peltz’s Trian Said to Amass Stake in Terminix-Owner Rentokil (2)
  • Heidelberg Materials (HEI TH) +1.9%
    • Heidelberg Materials Re-Initiated Buy at Bankhaus Metzler
  • Evotec SE (EVT TH) +1.7%
    • Evotec Gets $20M Research Payment From Bristol Myers Squibb
  • Aixtron (AIXA TH) +1.3%
  • NIBE Industrier (NJB TH) +1.2%
  • SAP (SAP TH) +1.2%
    • Watch SAP and Software Stocks as Oracle Reports Strong Bookings
  • Adyen (1N8 TH) +1%
  • AstraZeneca (ZEG TH) +0.9%
  • Reckitt (3RB TH) +0.8%
  • ASML (ASME TH) +0.7%
  • Unilever (UNVB TH) -0.6%
  • Aker BP (ARC TH) -0.6%
  • Coloplast (CBHD TH) -0.6%
  • BMW (BMW TH) -0.7%
  • BBVA (BOY TH) -1%
    • BBVA Cut to Underperform at BNPP Exane; PT 9.40 euros
  • HelloFresh (HFG TH) -1.1%
  • Porsche (P911 TH) -1.1%
    • Porsche, VW Deserve Full-Time Drivers at the Wheel: Chris Bryant
  • Mercedes (MBG TH) -1.2%
  • Anglo American (NGLB TH) -1.2%
  • Umicore (NVJP TH) -5.8%
    • Umicore Cuts FY Adjusted Ebitda Forecast, Misses Estimates

>>> TradeGate Pre-Market Indications

DAX:
  • Heidelberg Materials (HEI TH) +2%
    • Heidelberg Materials Re-Initiated Buy at Bankhaus Metzler
  • SAP (SAP TH) +1.2%
    • Watch SAP and Software Stocks as Oracle Reports Strong Bookings
MDAX:
  • Evotec SE (EVT TH) +2.3%
    • Evotec Gets $20M Research Payment From Bristol Myers Squibb
  • Aixtron (AIXA TH) +1.4%
  • Aroundtown (AT1 TH) +1.1%
  • HelloFresh (HFG TH) -1.1%
  • Stabilus (STM TH) -7.7%
    • Stabilus FY Revenue Forecast Misses Estimates
SDAX:
  • Thyssenkrupp Nucera AG & Co KGaa (NCH2 TH) +1.4%
  • Borussia Dortmund (BVB TH) +1.3%
  • Dermapharm (DMP TH) +1.2%
  • Deutsche PBB (PBB TH) +1%
  • RENK Group AG (R3NK TH) -1.1%
    • CalSTRS Backs Renk Group on 12 of 13 Proposals at June 26 AGM